Oxlumo Injection, Solution
Product Images NDC 71336-1002

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Oxlumo (NDC 71336-1002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alnylam Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Lumasiran 01)

Chemical structure diagram depicting the sense and antisense strands of the oligonucleotide component labeled L96 in lumasiran (OXLUMO). The diagram shows 5' to 3' sequences with nucleotide modifications and annotations for base pairing and chemical groups including phosphodiester and phosphorothioate linkages.*

FDA Label Image

Figure 1 (Lumasiran 02)

A line graph illustrating the percent change from baseline in 24-hour urinary oxalate levels over six months of treatment. The graph compares OXLUMO (lumasiran) injection 94.5 mg/.5 mL subcutaneous treatment with a placebo in two patient groups. Percent change is plotted on the vertical axis and study visits from baseline through month 6 on the horizontal axis. OXLUMO shows a marked decrease in urinary oxalate beginning at month 1, remaining consistently lower than placebo throughout the study period.*

FDA Label Image

Figure 2 (Lumasiran 03)

A line graph showing percent change from baseline in urinary oxalate to creatinine ratio (mmol/mmol) over six months of visits for patients treated with OXLUMO. The graph compares initial weight groups (<10 kg, 10-<20 kg, ≥20 kg) and all OXLUMO treated patients, with data points and error bars for each month from baseline to month 6.*

FDA Label Image

Principal Display Panel (0.5 mL Vial Carton)

Packaging label for OXLUMO (lumasiran) injection, 94.5 mg/0.5 mL, a subcutaneous injection solution. The label states it is for subcutaneous injection by healthcare professionals only and includes storage information (2°C to 25°C). It is manufactured for Alnylam Pharmaceuticals, Inc. and by Vetter Pharma-Fertigung GmbH & Co. KG, Germany. The label includes the NDC 71336-1002, a barcode, and usage instructions indicating one single-dose vial per package.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.